"Rising Competition in the Booming Weight Loss Drug Market"

Drugmakers are racing to enter the weight loss drug market, which is expected to be worth tens of billions in the next decade. Companies like Boehringer Ingelheim, Terns Pharmaceuticals, Viking Therapeutics, and Structure Therapeutics are developing weight loss drugs targeting gut hormones like GLP-1 and glucagon. With demand for obesity medications projected to grow, smaller players are aiming to compete with dominant companies like Novo Nordisk and Eli Lilly. Large pharmaceutical companies like Sanofi and Bayer are also considering entering the market through potential partnerships or next-generation weight loss drugs.